During the early-80s Dr. Mitchell S. Steiner realized there was more to being a urologist. He chose a route in molecular biology, something of an emerging field back then. His studies began in the pre-Viagra era; most approaches were invasive and castration was common for prostate cancer.
Somewhere in the first fifteen minutes of the interview I was reminded that urology and the medical profession would lead to mentions most men steer away from: castration, STDs., sperm count, gonads, prophylactics... Yet, it was highly interesting like a visiting professor's colloquium. Read the full interview and listen to additional soundbites at Seeking Alpha.
Disclosure: I am/we are long FHCO.
Buy-side analysis of stocks:
1. Gun Control Myths Resurface But Stocks Bounce Back
2. Making Babies? This Stock Counts On It.
3. Is The $136 Billion Debt Of General Electric A Deterrent?
4. Interview: Neptune Wellness Solutions CEO Jim Hamilton
Articles are written by Travis Brown at Seeking Alpha. Information covers stocks in the NASDAQ stock market and NYSE stock market.